Abstract 1260: First-in-class, orally bioavailable KRASG12V(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12Vmutant cancers
Abstract 1260: First-in-class, orally bioavailable KRASG12V(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12Vmutant cancers
复制标题
摘要 1260：首创、口服生物可利用的 KRASG12V(ON) 三复合物抑制剂，作为单药或联合用药，在 KRASG12V 突变癌症的临床前模型中发挥显着的抗肿瘤活性
DOI：
10.1158/1538-7445.am2021-1260
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
J. Smith
中科院分区：
文献类型：
--
作者：
E. Koltun;James Cregg;M. Rice;D. Whalen;Rebecca Freilich;Jingjing Jiang;R. Hansen;Alun Bermingham;J. Knox;J. Dinglasan;Kyle J. Seamon;C. Blaj;Stephanie S. Chang;Yang Liu;Jun Huang;K. Chou;Laura L. McDowell;Bianca J. Lee;D. Wildes;Zhengping Wang;Mallika Singh;Adrian L Gill;J. Smith
